Bristol Myers Shares Slip After Mixed Trial Results

what happened

Stocktwits reports that Bristol Myers Squibb (BMY) shares fell about 3% in Monday’s midday trading after opening higher. The move followed mixed findings from the late-stage ALOFT-IPF study of oral admilparant in idiopathic pulmonary fibrosis (IPF): the primary goal was met only with the 60 mg twice-daily regimen. After 52 weeks, patients on that dose posted a statistically significant change in forced vital capacity versus placebo, a standard lung-function measure. The 120 mg twice-daily regimen slowed the decline in lung function, but the result did not clear the threshold for statistical significance. Both doses were generally tolerated well, with few and similar treatment discontinuations caused by side effects compared with placebo. Bristol Myers said the results support admilparant’s potential as a first-in-class drug aimed at a defined biological pathway in progressive IPF. The company plans a complete data review and discussions with health authorities about potential regulatory submissions. More detailed findings are due at a future medical meeting; a separate late-stage trial in a broader type of progressive lung fibrosis is scheduled to produce results in early 2027.

The company also said an interim readout from ACTION-1 achieved its primary objective. RYZ101, an experimental radiopharmaceutical from Bristol Myers’ RayzeBio unit, delivered a statistically significant and clinically meaningful improvement in the time before disease progression for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) whose cancer had advanced after earlier lutetium-based therapy. The comparison included standard choices such as certain hormonal agents and other approved medicines. Safety results were consistent with the treatment’s established profile. Executives called the outcome an important milestone for patients with limited options and said they intend to engage regulators on the data. RYZ101 already has orphan-drug designation for the rare disease. The trial will continue monitoring overall survival, with full findings expected at a future medical conference.

Stocktwits said retail sentiment toward BMY remained in bearish territory over the previous 24 hours, while message activity stayed high. The shares are up 6% year to date.

why it matters

For markets, the update pairs dose-dependent results in lung fibrosis with a favorable cancer-therapy readout, leaving regulatory discussions and upcoming data as key areas of attention.

instruments